DK140837B - Analogifremgangsmåde til fremstilling af clathratforbindelser af prostaglandiner med cyclodextriner. - Google Patents

Analogifremgangsmåde til fremstilling af clathratforbindelser af prostaglandiner med cyclodextriner.

Info

Publication number
DK140837B
DK140837B DK279771AA DK279771A DK140837B DK 140837 B DK140837 B DK 140837B DK 279771A A DK279771A A DK 279771AA DK 279771 A DK279771 A DK 279771A DK 140837 B DK140837 B DK 140837B
Authority
DK
Denmark
Prior art keywords
prostaglandins
cyclodextrins
preparation
analogous process
clathrate compounds
Prior art date
Application number
DK279771AA
Other languages
English (en)
Other versions
DK140837C (da
Inventor
Masaki Hayashi
Atsunobu Ishihara
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of DK140837B publication Critical patent/DK140837B/da
Application granted granted Critical
Publication of DK140837C publication Critical patent/DK140837C/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Medical Informatics (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK279771AA 1970-06-10 1971-06-09 Analogifremgangsmåde til fremstilling af clathratforbindelser af prostaglandiner med cyclodextriner. DK140837B (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP45050119A JPS503362B1 (da) 1970-06-10 1970-06-10

Publications (2)

Publication Number Publication Date
DK140837B true DK140837B (da) 1979-11-26
DK140837C DK140837C (da) 1981-09-07

Family

ID=12850213

Family Applications (1)

Application Number Title Priority Date Filing Date
DK279771AA DK140837B (da) 1970-06-10 1971-06-09 Analogifremgangsmåde til fremstilling af clathratforbindelser af prostaglandiner med cyclodextriner.

Country Status (22)

Country Link
US (1) US3816393A (da)
JP (1) JPS503362B1 (da)
AT (1) AT332570B (da)
BE (1) BE768288A (da)
CA (1) CA958007A (da)
CH (1) CH568259A5 (da)
CS (1) CS170169B2 (da)
CY (1) CY895A (da)
DE (1) DE2128674C2 (da)
DK (1) DK140837B (da)
ES (1) ES392074A1 (da)
FR (1) FR2100745B1 (da)
GB (1) GB1351238A (da)
HK (1) HK17577A (da)
HU (1) HU163135B (da)
IE (1) IE35326B1 (da)
NL (1) NL162901C (da)
NO (1) NO134373C (da)
RO (1) RO62182A (da)
SE (1) SE390818B (da)
SU (1) SU404225A3 (da)
ZA (1) ZA713398B (da)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163108A (en) * 1967-02-16 1979-07-31 Lever Brothers Company Prostaglandins
US4054736A (en) * 1970-06-10 1977-10-18 Ono Pharmaceutical Co., Ltd. Clathrate compounds of prostaglandins or their analogues with cyclodextrin
US3954833A (en) * 1971-04-12 1976-05-04 The Upjohn Company 16,16-Methyl and ethyl substituted PGF2.sub.α compounds
CA984387A (en) * 1971-04-12 1976-02-24 Barney J. Magerlein Analogs of prostaglandins
US3903131A (en) * 1971-04-12 1975-09-02 Upjohn Co 16 and 16,16-dimethyl PGE{HD 2{B
FR2134673A1 (en) * 1971-04-30 1972-12-08 Ono Pharmaceutical Co Novel optically active isomers of prostaglandin analoguesof natural configuration useful as hypotensive agents, diuretics,contraceptives, for treating gastric ulcer and asthma, and forinhibiting platelet aggregation
US4045467A (en) * 1972-02-18 1977-08-30 May & Baker Limited Cyclopentane derivatives
US4082789A (en) * 1972-03-28 1978-04-04 The University Court Of The University Of Edinburgh Prostaglandins C2
JPS4926258A (da) * 1972-07-06 1974-03-08
US4130721A (en) * 1972-07-24 1978-12-19 The Upjohn Company 11-Deoxy PGE2 compounds
US4110368A (en) * 1972-07-24 1978-08-29 American Cyanamid Company Hydro substituted prostanoic acids and esters
US4141914A (en) * 1972-07-24 1979-02-27 American Cyanamid Company Novel 11-deoxy-11-substituted prostaglandins of the E and F series
JPS4942648A (da) * 1972-08-24 1974-04-22
US3962312A (en) * 1972-09-21 1976-06-08 Ono Pharmaceutical Company 9,11,15-Trihydroxy prost-5-enoic acid analogues
JPS5443570B2 (da) * 1972-10-27 1979-12-20
US3972917A (en) * 1972-10-27 1976-08-03 American Home Products Corporation 11-Deoxy 15-methyl prostaglandin E1
US4092427A (en) * 1973-04-16 1978-05-30 American Home Products Corporation Method of inducing abortion using alkyl derivatives of prostanoic acids
JPS5623984B2 (da) * 1973-04-19 1981-06-03
US4052446A (en) * 1973-08-06 1977-10-04 Hoffmann-La Roche Inc. 11,16-substituted prostaglandins
US4059576A (en) * 1973-08-06 1977-11-22 Hoffmann-La Roche, Inc. 11-Substituted prostaglandins
US4246426A (en) * 1973-08-06 1981-01-20 Hoffmann-La Roche Inc. 11-Substituted prostaglandins
US4026927A (en) * 1973-09-25 1977-05-31 Yamanouchi Pharmaceutical Co., Ltd. Novel prostaglandin derivatives
US4036954A (en) * 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
GB1448268A (en) * 1973-11-13 1976-09-02 May & Baker Ltd Cyclopentane derivatives
GB1441564A (en) * 1974-02-07 1976-07-07 Upjohn Co Prostaglandins
US4041066A (en) * 1974-02-07 1977-08-09 The Upjohn Company 4,5-Cis-didehydro-PGE1 compounds
DE2416193C2 (de) * 1974-04-03 1985-08-14 Hoechst Ag, 6230 Frankfurt Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie ihre Verwendung als cytoprotektives Mittel
US4256651A (en) * 1974-10-02 1981-03-17 The Upjohn Company 2a,2b-Dihomo-15-alkyl-PGF1β compounds
US3974195A (en) * 1974-10-02 1976-08-10 The Upjohn Company 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
GB1482010A (en) * 1974-10-28 1977-08-03 Ono Pharmaceutical Co Prostaglandin analogues
DK142235B (da) * 1974-12-20 1980-09-29 Yamanouchi Pharma Co Ltd Analogifremgangsmåde til fremstilling af 20-alkoxy-16-methyl-prostadiensyre-derivater.
US4209637A (en) * 1975-02-24 1980-06-24 The Upjohn Company 2,2-Difluoro-PGF2 analogs
US4207420A (en) * 1975-02-24 1980-06-10 The Upjohn Company 2,2-Difluoro-PGF1 analogs
US4059701A (en) * 1975-04-17 1977-11-22 American Home Products Corporation 15-Substituted prostanoic acids for treating bronchial spasm
FR2313019A2 (fr) * 1975-06-04 1976-12-31 Ono Pharmaceutical Co Nouveaux analogues de prostaglandines et leur procede de preparation
US4086269A (en) * 1975-07-07 1978-04-25 American Home Products Corporation 11-Deoxy-15-substituted prostaglandins
US4026909A (en) * 1975-07-14 1977-05-31 The Upjohn Company Cis-13-PGF2.sub.α analogs
US4016184A (en) * 1975-09-17 1977-04-05 The Upjohn Company 9-Deoxy-9,10-didehydro-PGD1 compounds
US4033989A (en) * 1975-09-17 1977-07-05 The Upjohn Company 9-Deoxy-PGF2 Analogs
US4013695A (en) * 1975-10-02 1977-03-22 The Upjohn Company 4,4,5,5-Tetradehydro-PGE1 analogs
US4053502A (en) * 1975-10-02 1977-10-11 The Upjohn Company 4,4,5,5-Tetradehydro-ω-aryl-PGE1 analogs
US4053500A (en) * 1975-10-02 1977-10-11 The Upjohn Company 4,4,5,5-Tetradehydro-ω-aryl-PGF1α analogs
US4026919A (en) * 1975-10-23 1977-05-31 The Upjohn Company PGD2 Substituted esters
US4058665A (en) * 1975-11-06 1977-11-15 Yamanouchi Pharmaceutical Co., Ltd. Novel 3,15-dilower alkyl PGE2 derivatives
US4212986A (en) * 1976-09-17 1980-07-15 The Upjohn Company 2,2-Difluoro-PGE2 analogs
US4212987A (en) * 1976-09-17 1980-07-15 The Upjohn Company 2,2-Difluoro-PGE1 analogs
US4169895A (en) * 1976-09-28 1979-10-02 Pfizer Inc. Antisecretory 16,16-dimethyl-17-oxaprostaglandins
JPS53136513A (en) * 1977-05-06 1978-11-29 Ono Pharmaceut Co Ltd Stabilization of prostaglandin-x-related compounds
HU179141B (da) * 1977-09-23 1982-08-28
JPS5577440U (da) * 1978-11-25 1980-05-28
US4244883A (en) * 1979-09-12 1981-01-13 The Upjohn Company 2a,2b-Dihomo-15-alkyl-PGF2β compounds
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
DE3504044A1 (de) * 1985-02-04 1986-08-07 Schering AG, Berlin und Bergkamen, 1000 Berlin 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
DE3740838A1 (de) * 1987-11-27 1989-06-08 Schering Ag Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel
BE1001704A3 (fr) * 1987-12-22 1990-02-13 Glaxo Group Ltd Compositions aqueuses contenant un derive de l'acide piperidinylcyclopentylheptenoique.
US5221695A (en) * 1987-12-22 1993-06-22 Glaxo Group Limited Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
DE19828881A1 (de) * 1998-06-22 1999-12-23 Schering Ag Oxidationsinhibitor bei Prostan-Derivaten
US6287603B1 (en) 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
TWI313608B (en) 2001-07-23 2009-08-21 Ono Pharmaceutical Co Lower bone mass treating agent containing er4 agonist as active ingredient
TW200413000A (en) 2002-10-10 2004-08-01 Ono Pharmaceutical Co Intrinsic repair factor producing accelerator
WO2005009468A1 (ja) 2003-07-25 2005-02-03 Ono Pharmaceutical Co., Ltd. 軟骨関連疾患治療剤
CN100542537C (zh) * 2004-07-27 2009-09-23 中国人民解放军军事医学科学院毒物药物研究所 前列腺素e1口腔制剂
AU2006259878A1 (en) * 2005-06-13 2006-12-28 Cargill, Incorporated Cyclodextrin inclusion complexes and methods of preparing same
JP2008546386A (ja) * 2005-06-13 2008-12-25 カーギル インコーポレイテッド シクロデキストリン包接複合体及びその製造方法
JP2009539978A (ja) * 2006-06-13 2009-11-19 カーギル インコーポレイテッド 大粒子シクロデキストリン包接複合体及びその製造方法
WO2008083213A2 (en) * 2006-12-27 2008-07-10 Cargill, Incorporated Stabilisation by preparing cyclodextrin inclusion complexes
KR101492552B1 (ko) 2007-02-16 2015-02-12 오노 야꾸힝 고교 가부시키가이샤 요 배출 장애 치료제
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
US20080283693A1 (en) * 2007-05-15 2008-11-20 Evans Michael J F Propulsion apparatus and system
BRPI1013152B1 (pt) 2009-06-10 2019-06-18 Ono Pharmaceutical Co., Ltd. Composto, composição farmacêutica e medicamento que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais
JP4890657B1 (ja) * 2011-06-03 2012-03-07 小野薬品工業株式会社 リマプロストとβ−シクロデキストリンを含有する錠剤
JP6052175B2 (ja) 2011-08-02 2016-12-27 小野薬品工業株式会社 左室拡張機能改善剤
CN104603117B (zh) 2012-08-31 2018-03-23 小野药品工业株式会社 胺盐及其晶体
PT3456710T (pt) 2016-05-09 2021-09-02 Agc Inc Novo derivado de prostaglandina
JPWO2023037934A1 (da) * 2021-09-13 2023-03-16

Also Published As

Publication number Publication date
NL162901C (nl) 1980-07-15
IE35326B1 (en) 1976-01-07
US3816393A (en) 1974-06-11
ATA480371A (de) 1976-01-15
CS170169B2 (da) 1976-08-27
GB1351238A (en) 1974-04-24
ZA713398B (en) 1972-01-26
CH568259A5 (da) 1975-10-31
NO134373C (da) 1976-09-29
DE2128674C2 (de) 1982-06-24
ES392074A1 (es) 1974-08-01
JPS503362B1 (da) 1975-02-04
NO134373B (da) 1976-06-21
RO62182A (da) 1977-07-15
CY895A (en) 1977-10-07
BE768288A (fr) 1971-11-03
CA958007A (en) 1974-11-19
IE35326L (en) 1971-12-10
AT332570B (de) 1976-10-11
NL162901B (nl) 1980-02-15
SE390818B (sv) 1977-01-24
FR2100745B1 (da) 1974-08-30
DE2128674A1 (de) 1971-12-16
HU163135B (da) 1973-06-28
HK17577A (en) 1977-04-22
DK140837C (da) 1981-09-07
SU404225A3 (da) 1973-10-26
NL7107894A (da) 1971-12-14
FR2100745A1 (da) 1972-03-24

Similar Documents

Publication Publication Date Title
DK140837B (da) Analogifremgangsmåde til fremstilling af clathratforbindelser af prostaglandiner med cyclodextriner.
DK128733B (da) Fremgangsmåde til fremstilling af prostaglandinestere.
DK132174B (da) Analogifremgangsmåde til fremstilling af 2,4-diamino-5-benzylpyrimider.
DK129339B (da) Analogifremgangsmåde til fremstilling af N-aminophenylamidiner.
DK127640B (da) Fremgangsmåde til fremstilling af 3,20-dioxo-17α-21-dimethyl-19-norpregna-4,9-dien.
DK135455B (da) Fremgangsmåde til fremstilling af 7-halogen-7-desoxythiolincosaminider.
DK130467B (da) Fremgangsmåde til fremstilling af erythromycylaminer.
DK136975B (da) Analogifremgangsmåde til fremstilling af phenazinderivater.
DK126998B (da) Analogifremgangsmåde til fremstilling af amino-s-triazolylbenzensulfonamidforbindelser.
DK127977B (da) Fremgangsmåde til fremstilling af 6α-methyl-19-nor-pregnener.
DK127812B (da) Analogifremgangsmåde til fremstilling af 3,5-dibrom-zearalan.
DK129453B (da) Analogifremgangsmåde til fremstilling af 1-aminoisoquinoliner.
DK137181B (da) Analogifremgangsmåde til fremstilling af 3-amino-kinolinderivater.
DK128205B (da) Fremgangsmåde til fremstilling af 1-aryloxy-2-propanoler.
DK126323B (da) Fremgangsmåde til fremstilling af 3β-hydroxy-5α-cardenolider eller -bufadienolider.
DK127001B (da) Fremgangsmåde til fremstilling af alkylsilaner.
DK137860B (da) Analogifremgangsmåde til fremstilling af triazolobenzodiazepin-5N-oxydderivater.
DK125388B (da) Fremgangsmåde til fremstilling af phenylaminoethanolderivater.
DK129993B (da) Analogifremgangsmåde til fremstilling af indoleddikesyrederivater.
DK127414B (da) Analogifremgangsmåde til fremstilling af phenylhydrazider.
DK127852B (da) Analogifremgangsmåde til fremstilling af 22-substituerede cardenolidrhamnosider.
DK129049B (da) Analogifremgangsmåde til fremstilling af α-aminobenzylpenicillinderivater.
DK128209B (da) Analogifremgangsmåde til fremstilling af 19-nor-14-dehydrotestosteronderivater.
DK129138B (da) Fremgangsmåde til fremstilling af tuberactinomycin-N.
DK125790B (da) Fremgangsmåde til fremstilling af L-β-3,4-dihydroxyphenyl-α-alanin.

Legal Events

Date Code Title Description
PBP Patent lapsed